Terfenadine-β-cyclodextrin inclusion complex with antihistaminic activity enhancement

被引:45
作者
Choi, HG
Lee, BJ
Han, JH
Lee, MK
Park, KM
Yong, CS
Rhee, JD
Kim, YB
Kim, CK
机构
[1] Seoul Natl Univ, Coll Pharm, Kwanak Ku, Seoul 151742, South Korea
[2] Yeungnam Univ, Coll Pharm, Kyongsan 712749, South Korea
[3] Kangweon Natl Univ, Coll Pharm, Chunchon 200701, South Korea
关键词
antihistaminic activity; inclusion; solubility; terfenadine;
D O I
10.1081/DDC-100107250
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Terfenadine, an antihistaminic drug, has relatively low bioavailability after oral administration due to its limited solubility in water. To enhance the antihistaminic activity of terfenadine, the terfenadine-beta -cyclodextrin (1:2) inclusion complex was prepared by the neutralization method. The solubility and dissolution of the inclusion complex were carried out, and its antihistaminic activity was then evaluated and compared with terfenadine powder by the passive subcutaneous anaphylaxis method in rats. The formation constant of the inclusion complex was higher at lower pH, while its formation ratio was 1:2 irrespective of pH. For terfenadine, it improved the solubility 200 times and the dissolution rate 5 times. It gave a low histamine level at 30 min, followed by a sustained low level until 60 min, while terfenadine powder gave a low histamine level at 60 min, suggesting that it had faster and more effective antihistaminic activity than terfenadine powder in rats due to fast dissolution and absorption of terfenadine. It is concluded that this inclusion complex enhanced the antihistaminic activity of terfenadine following the enhanced solubility and dissolution of terfenadine.
引用
收藏
页码:857 / 862
页数:6
相关论文
共 15 条
[1]   Improved bioavailability and clinical response in patients with chronic liver disease following the administration of a spironolactone: beta-cyclodextrin complex [J].
AbosehmahAlbidy, AZM ;
York, P ;
Wong, V ;
Losowsky, MS ;
Chrystyn, H .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 44 (01) :35-39
[2]  
AMMAR HO, 1996, PHARMAZIE, V51, P1
[3]   CYCLODEXTRINS IN THE PHARMACEUTICAL FIELD [J].
BEKERS, O ;
UIJTENDAAL, EV ;
BEIJNEN, JH ;
BULT, A ;
UNDERBERG, WJM .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1991, 17 (11) :1503-1549
[4]   SOLUTION STABILITY STUDY OF TERFENADINE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
CHEN, TM ;
SILL, AD ;
HOUSMYER, CL .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1986, 4 (04) :533-539
[5]  
ElNahhas SA, 1997, PHARMAZIE, V52, P624
[6]   BETA-CYCLODEXTRIN DERIVATIVES, SBE4-BETA-CD AND HP-BETA-CD, INCREASE THE ORAL BIOAVAILABILITY OF CINNARIZINE IN BEAGLE DOGS [J].
JARVINEN, T ;
JARVINEN, K ;
SCHWARTING, N ;
STELLA, VJ .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1995, 84 (03) :295-299
[7]  
JAYANTHI G, 1995, PHARMAZIE, V50, P769
[8]  
KIM CK, 1987, ARCH PHARM RES, V10, P69
[9]  
MARTIN U, 1978, ARZNEIMITTELFORSCH, V28-1, P770
[10]  
MENHENDRE RP, 1993, INDIAN DRUGS, V30, P494